The role of age in neuroblastoma risk stratification: The German, Italian, and children's oncology group perspectives

Cancer Letters

Volumn 228, Issue 1-2, 2005, Pages 257-266

  London, Wendy B ^a   Boni, Luca ^b   Simon, Thorsten ^c   Berthold, Frank ^d   Twist, Clare ^e   Schmidt, Mary Lou ^f   Castleberry, Robert P ^g   Matthay, Katherine K ^h   Cohn, Susan L ^a   De Bernardi, Bruno ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF COLOGNE   (Germany)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Age; Neuroblastoma; Prognosis; Risk factors

Indexed keywords

ANALYTIC METHOD; CANCER RISK; CHILD; CHILDHOOD CANCER; GERMANY; HIGH RISK POPULATION; HUMAN; ITALY; NEUROBLASTOMA; ORGANIZATION; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY;

EID: 23944448064     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.12.054     Document Type: Review

References (32)

1. D. Plantaz, J. Vandesompele, N. Van Roy, M. Lastowska, N. Bown, and V. Combaret Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification Int. J. Cancer 91 2001 680 686
2. R. Spitz, B. Hero, K. Ernestus, and F. Berthold Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastomam Clin. Cancer Res. 9 2003 52 58
3. M. Gehring, F. Berthold, L. Edler, M. Schwab, and L.C. Amler The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma Cancer Res. 55 1995 5366 5369
4. H. Caron, P. van Sluis, R. Buschman, R. Pereira do Tanque, P. Maes, and L. Beks Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma N. Engl. J. Med. 334 1996 225 230
5. A.T. Look, F.A. Hayes, R. Nitschke, N.B. McWilliams, and A.A. Green Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma N. Engl. J. Med. 311 1984 231 235
6. H. Shimada, J. Chatten, W.A. Newton Jr, N. Sachs, A.B. Hamoudi, and T. Chiba Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas J. Natl Cancer Inst. 73 1984 405 416
7. V.V. Joshi, A.B. Cantor, G. Altshuler, E.W. Larkin, J.S. Neill, and J.J. Shuster Age-linked prognostic categorization based on a new histologic grading system of neuroblastomas. A clinicopathologic study of 211 cases from the Pediatric Oncology Group Cancer 69 1992 2197 2211
8. E.I. Smith, G.M. Haase, R.C. Seeger, and G.M. Brodeur A surgical perspective on the current staging in neuroblastoma - the International Neuroblastoma Staging System proposal J. Pediatr. Surg. 24 1989 386 390
9. G.M. Brodeur, J. Pritchard, F. Berthold, N.L. Carlsen, V. Castel, and R.P. Castelberry Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment J. Clin. Oncol. 11 1993 1466 1477
10. N. Breslow, and B. McCann Statistical estimation of prognosis for children with neuroblastoma Cancer Res. 31 1971 2098 2103
11. A.E. Evans, G.J. D'Angio, H.N. Sather, A.A. de Lorimier, A. Dalton, and R.S. Ungerleider A comparison of four staging systems for localized and regional neuroblastoma: a report from the Children's Cancer Study Group J. Clin. Oncol. 8 1990 678 688
12. F. Berthold, R. Kassenbohmer, and J. Zieschang Multivariate evaluation of prognostic factors in localized neuroblastoma: a report from the Children's Cancer Study Group J. Clin. Oncol. 8 1990 678 688
13. T. Saito, Y. Tsunematsu, M. Saeki, T. Honna, E. Masaki, Y. Kojima, and J. Miyauchi Trends of survival in neuroblastoma and independent risk factors for survival at a single institution Med. Pediatr. Oncol. 29 1997 197 205
14. M.L. Schmidt, A. Lal, and R. Seeger Favorable prognosis for patients ages 12-18 months with stage 4 MYCN-nonamplified neroblastoma Proc. Am. Soc. Clin. Oncol. 22 2003 800 [abstr 3214]
15. R. George, W.B. London, J.M. Maris, S.L. Cohn, L. Diller, and A.T. Look Age as a continuous variable in predicting outcome for neuroblastoma patients with metastatic disease: impact of tumor biologic features Proc. Am. Soc. Clin. Oncol. 22 2003 799
16. G.M. Brodeur, J. Pritchard, F. Berthold, N.L. Carlsen, V. Castel, and R.P. Castelberry Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment J. Clin. Oncol. 11 1993 1466 1477
17. P. Kaatsch, and C. Spix Annual report 2003 2004 German Childhood Cancer Registry Mainz 1466 1477
18. F. Berthold, B. Hero, B. Kremens, R. Handgretinger, G. Henze, and F.H. Schilling Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age Cancer Lett. 197 2003 11 17
19. T. Simon, R. Spitz, A. Faldum, B. Hero, and F. Berthold New definition of low risk neuroblastoma using stage, age, and 1p and MYCN status J. Pediatr. Hematol. Oncol. 26 2004 791 796
20. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J. Am. Stat. Assoc. 53 1958 457 481
21. M.L. Schmidt, J.N. Lukens, R.C. Seeger, G.M. Brodeur, H. Shimada, and R.B. Gerbing Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children's Cancer Group study J. Clin. Oncol. 18 2000 1260 1268
22. K.K. Matthay, C. Perez, R.C. Seeger, G.M. Brodeur, H. Shimada, and J.B. Atkinson Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study J. Clin. Oncol. 16 1998 1256 1264
23. K.K. Matthay, J.G. Villablanca, R.C. Seeger, D.O. Stram, R.E. Harris, and N.K. Ramsay Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid N. Engl. J. Med. 341 1999 1165 1173
24. R. Peto, and J. Peto Asymptotically efficient rank invariant test procedures, JRSSA 135 1972 185 198
25. C.S. Alvarado, W.B. London, A.T. Look, G.M. Brodeur, D.H. Altmiller, and P.S. Thorner Natural history and biology of stage A neuroblastoma: a pediatric oncology group study J. Pediatr. Hematol. Oncol. 22 2000 197 205
26. K.K. Matthay, M.C. O'Leary, N.K. Ramsay, J. Villablanca, C.P. Reynolds, and J.B. Atkinson Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results Eur. J. Cancer 31 1995 197 205
27. D.R. Cox Regression models and life tables (with discussion) JRSSB 34 1972 187 220
28. M. Mazumdar, A. Smith, and J. Bacik Methods for categorizing a prognostic variable in a multivariable setting Stat. Med. 22 2003 559 571
29. D. Faraggi, and R. Simon A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis Stat. Med. 15 1996 2203 2213
30. D.G. Altman, B. Lausen, W. Sauerbrei, and M. Schumacher Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors J. Natl Cancer Inst. 86 1994 829 835
31. F.E. Harrell Jr, K.L. Lee, R.M. Califf, D.B. Pryor, and R.A. Rosati Regression modelling strategies for improved prognostic prediction Stat. Med. 3 1984 143 152
32. A.R. Feinstein Multivariable analysis: an introduction 1996 Yale University Press Haven, CT 184 187 [578-582]